Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

252 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cunningham D, et al. N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025. N Engl J Med. 2004. PMID: 15269313 Clinical Trial.
Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.
Barbier A, Domont J, Magné N, Goldmard JL, Genestie C, Hannoun C, Vaillant JC, Bellanger A, Khayat D, Capron F, Spano JP. Barbier A, et al. Bull Cancer. 2010 Feb;97(2):E9-E15. doi: 10.1684/bdc.2010.1033. Bull Cancer. 2010. PMID: 20085858
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.
Spano JP, Vano Y, Vignot S, De La Motte Rouge T, Hassani L, Mouawad R, Menegaux F, Khayat D, Leenhardt L. Spano JP, et al. Med Oncol. 2012 Sep;29(3):1421-8. doi: 10.1007/s12032-011-0070-2. Epub 2011 Sep 25. Med Oncol. 2012. PMID: 21947747 Clinical Trial.
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Khayat D, Chollet P, Antoine EC, Monfardini S, Ambrosini G, Benhammouda A, Mazen MF, Sorio R, Borg-Olivier O, Riva A, Ramazeilles C, Azli N. Khayat D, et al. J Clin Oncol. 2001 Jul 15;19(14):3367-75. doi: 10.1200/JCO.2001.19.14.3367. J Clin Oncol. 2001. PMID: 11454884 Clinical Trial.
Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer.
Gil-Delgado MA, Antoine EC, Guinet F, Bassot V, Grapin JP, Benhammonda A, Adam R, Castaing D, Bismuth H, Khayat D. Gil-Delgado MA, et al. Am J Clin Oncol. 2001 Jun;24(3):251-4. doi: 10.1097/00000421-200106000-00008. Am J Clin Oncol. 2001. PMID: 11404495 Clinical Trial.
European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
Khayat D, Gil-Delgado M, Antoine EC, Coeffic D, Benhammouda A, Grapin JP, Bastian G. Khayat D, et al. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):64-7. Oncology (Williston Park). 1998. PMID: 9726094 Review.
Impact of EGFR expression on colorectal cancer patient prognosis and survival.
Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, Raphael M, Penault-Llorca F, Breau JL, Fagard R, Khayat D, Wind P. Spano JP, et al. Ann Oncol. 2005 Jan;16(1):102-8. doi: 10.1093/annonc/mdi006. Ann Oncol. 2005. PMID: 15598946
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer.
Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey P, Dalgleish A, Johnston C, Banks RE, Selby PJ. Patel PM, et al. Eur J Cancer. 2008 Jan;44(2):216-23. doi: 10.1016/j.ejca.2007.11.003. Eur J Cancer. 2008. PMID: 18164612 Clinical Trial.
252 results
Jump to page
Feedback